Research Topics
| William BergerSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitisWilliam E Berger
Allergy and Asthma Associates of Southern California, Mission Viejo, California 92691, USA
Allergy Asthma Proc 27:214-23. 2006..All treatments were well tolerated. Desloratadine, 5 mg, and fexofenadine, 180 mg, provide comparable efficacy and tolerability in the treatment of SAR. Both treatments are significantly more effective than placebo...- The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ)Michael Alexander
Niagara Clinical Research, 5673 North Street, Niagara Falls, Ont L2G1J4, Canada
Health Qual Life Outcomes 3:67. 2005..The purpose of this study was to present the results of the psychometric validation of the EAPIQ... - Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhalerWilliam E Berger
Allergy and Asthma Associates of Southern California, Mission Viejo, California 92691 6410, USA
J Asthma 47:447-59. 2010..The objective was to review efficacy, safety, and pharmacogenetic data on budesonide/formoterol pMDI in the treatment of persistent asthma... - Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with anti-immunoglobulin E antibodyWilliam E Berger
Mission Viejo Medical Center, Mission Viejo, California 92691, USA
Allergy Asthma Proc 27:S29-32. 2006.... - The safety and efficacy of desloratadine for the management of allergic diseaseWilliam E Berger
Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, California, USA
Drug Saf 28:1101-18. 2005..In addition, it has been shown to not interact with concomitantly administered drugs and food. Overall, current data indicate that desloratadine is a safe and effective treatment for allergic diseases... - Paediatric pulmonary drug delivery: considerations in asthma treatmentWilliam E Berger
Allergy and Asthma Associates of Southern California, Mission Viejo, CA 92691 6410, USA
Expert Opin Drug Deliv 2:965-80. 2005..Although age-based device recommendations have been made, the optimal choice for drug delivery is the one that the patient or caregiver prefers to use, can use correctly and is most likely to use consistently... - Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapyWilliam Berger
Southern California Research, Mission Viejo, California, USA
Ann Allergy Asthma Immunol 95:361-71. 2005..The Rhinoconjunctivitis Quality of Life Questionnaire and the Allergic Conjunctivitis Quality of Life Questionnaire quantify separate aspects of QoL... - Budesonide inhalation suspension for the treatment of asthma in infants and childrenWilliam E Berger
Allergy and Asthma Associates of Southern California, Mission Viejo, California 92691 6410, USA
Drugs 65:1973-89. 2005..However, available evidence suggests that growth effects are transient in children receiving budesonide and that these children eventually achieve full adult height... - The use of inhaled formoterol in the treatment of asthmaWilliam E Berger
Allergy and Asthma Associates of Southern California, Mission Viejo, California 92691 6410, USA
Ann Allergy Asthma Immunol 97:24-33. 2006..To discuss the clinical efficacy and safety of formoterol when used to relieve symptoms of asthma and prevent exercise-induced bronchoconstriction (EIB)... - Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitisWilliam Berger
Southern California Research, Mission Viejo 92691, USA
Ann Allergy Asthma Immunol 97:375-81. 2006.... - Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthmaWilliam E Berger
Allergy and Asthma Associates, Mission Viejo, California 92691, USA
Ann Allergy Asthma Immunol 97:672-80. 2006..Mometasone furoate dry powder inhaler (DPI) has been shown to effectively treat asthma in children... - Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary diseaseW E Berger
Allergy and Asthma Associates of Southern California, 27800 Medical Asthma Associates, Suite 244, Mission Viejo, CA 92691, USA
Respir Med 102:173-88. 2008.... - Once-daily olopatadine ophthalmic solution 0.2% in the treatment of allergic conjunctivitis and rhinoconjunctivitisWilliam E Berger
Clinical Professor, Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, CA, USA Allergy and Asthma Associates, 27800 Medical Center Road, Suite 244, Mission Viejo, CA 92691, USA
Expert Rev Pharmacoecon Outcomes Res 7:221-6. 2007..This review article will summarize literature reports on the 0.2% formulation of olopatadine from the standpoint of efficacy, safety, total treatment costs, therapeutic outcomes, patient compliance and effect on quality of life... - Efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler: randomized controlled trial comparing once- and twice-daily dosing in patients with asthmaWilliam E Berger
Allergy and Asthma Associates, 27800 Medical Center Road, Mission Viejo, CA 92691, USA
Allergy Asthma Proc 31:49-59. 2010..Once- or twice-daily BUD/FM showed better efficacy than BUD once daily or PBO; results generally were more favorable with twice-daily dosing compared with both once-daily dosing regimens, which had one-half the daily FM dose... - The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in childrenWilliam E Berger
Allergy and Asthma Associates of Southern California, 27800 Medical Center Road Number 244, Mission Viejo, CA 29691 6410, USA
Allergy Asthma Proc 31:26-39. 2010..007). In this 26-week study of asthmatic children (6-11 years), safety profiles were similar and clinical benefits were greater with budesonide/formoterol than with budesonide... - Safety and efficacy of olopatadine hydrochloride nasal spray 0.6% in pediatric subjects with allergic rhinitisWilliam E Berger
Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, California, USA
Allergy Asthma Proc 30:612-23. 2009..In subjects 6 to <12 years of age, OLO was superior to vehicle in the treatment of SAR. In subjects 2 to <12 years of age, OLO had an overall low rate of AEs and low systemic exposure... - Aerosol devices and asthma therapyWilliam Berger
Allergy and Asthma Associates of Southern CA, 27800 Medical Center Road, Suite 244, Mission Viejo, CA 92691 6410, USA
Curr Drug Deliv 6:38-49. 2009.... - Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine hydrochloride nasal spray in patients with chronic rhinitisWilliam E Berger
Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, USA
Expert Opin Drug Metab Toxicol 5:91-102. 2009.... - Ciclesonide: a closer look at its systemic and oropharyngeal safety profileWilliam E Berger
Allergy and Asthma Associates, 27800 Medical Center Road, Mission Viejo, CA 92691, USA
Curr Drug Saf 1:265-70. 2006..The favorable safety profile of ciclesonide suggests a conferred benefit to asthma patients treated with this novel ICS... - Mometasone furoate/formoterol in the treatment of persistent asthmaWilliam E Berger
Allergy and Asthma Associates, 27800 Medical Center Road, Suite 244, Mission Viejo, CA, USA
Expert Rev Respir Med 5:739-46. 2011..Clinical safety studies lasting up to 1 year have found that MF/F has a low incidence of local and systemic side effects... - Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheezeWilliam E Berger
Allergy and Asthma Associates of Southern California, Mission Viejo, CA 92691, USA
J Pediatr 146:91-5. 2005..To compare the safety of budesonide inhalation suspension (BIS) with placebo in infants 6 to 12 months of age with mild to moderate persistent asthma or recurrent wheeze... - Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthmaWilliam E Berger
Southern California Research, Mission Viejo, California 92691, USA
Ann Allergy Asthma Immunol 90:583-91; quiz 591-2, 659. 2003..To review the rationale supporting the use of levalbuterol [(R)-albuterol] for the treatment of pediatric and adult asthma... - Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitisWilliam E Berger
Southern California Research, Mission Viejo, USA
Otolaryngol Head Neck Surg 129:16-23. 2003..Nasal symptom (discharge, stuffiness, itching, sneezing) severity was recorded twice daily; total nasal symptom score was calculated. Health-related quality of life was assessed by Rhinoconjunctivitis Quality of Life Questionnaire... - Overview of allergic rhinitisWilliam E Berger
Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, California, USA
Ann Allergy Asthma Immunol 90:7-12. 2003..Half the patients with allergic rhinitis experience symptoms up to 4 months per year, whereas 20% are symptomatic more than 9 months of the year. This disease is often associated with asthma, sinusitis, and otitis media... - Treatment of acute bronchospasm in elderly patientsWilliam E Berger
Department of Pediatrics, Division of Allergy and Immunology, College of Medicine, University of California, Irvine, USA
Postgrad Med 118:34-7; discussion 38. 2005..This paper presents results from clinical studies examining levalbuterol and racemic albuterol use among elderly patients who have asthma or COPD... - Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestionWilliam E Berger
Southern California Research, Mission Viejo, California 92691, USA
Ann Allergy Asthma Immunol 89:485-91. 2002..A nonsedating antihistamine that significantly decreases nasal congestion and improves symptoms of seasonal allergic asthma would be a significant advance in therapy... - Efficacy and safety of fluticasone propionate 250 microg administered once daily in patients with persistent asthma treated with or without inhaled corticosteroidsWilliam E Berger
Ann Allergy Asthma Immunol 89:393-9. 2002..Studies have shown fluticasone propionate (FP) 100, 200, and 500 microg administered once daily to be effective in the treatment of asthma. The efficacy of a once daily regimen of FP 250 microg has not been evaluated previously... - Allergic rhinitis in childrenW E Berger
Allergy and Asthma Associates, 27800 Medical Center Road, Suite 244, Mission Viejo, CA 92691, USA
Curr Allergy Asthma Rep 1:498-505. 2001.... - Monoclonal anti-IgE antibody: a novel therapy for allergic airways diseaseWilliam E Berger
Southern California Research, Mission Viejo 92691, USA
Ann Allergy Asthma Immunol 88:152-60; quiz 161-2, 208. 2002..To anticipate the likely effects (efficacy and safety) in clinical use in patients with allergic asthma and with allergic rhinitis. To characterize the types of patients who might benefit from this therapy... - Allergic rhinitis in children : diagnosis and management strategiesWilliam E Berger
Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, California, USA
Paediatr Drugs 6:233-50. 2004.... - Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadineWilliam E Berger
Southern California Research Center, Mission Viejo, California 92691, USA
Ann Allergy Asthma Immunol 91:205-11. 2003.... - Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthmaWilliam Berger
Mission Viejo Medical Center, Mission Viejo, California, USA
Ann Allergy Asthma Immunol 91:182-8. 2003..To evaluate the long-term effects of the anti-IgE antibody omalizumab in children with asthma... - One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthmaGeorge Bensch
Georgetown Place, Stockton, California, USA
Ann Allergy Asthma Immunol 89:180-90. 2002..However, this treatment requires close disease monitoring to detect early signs of acute exacerbation... - Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trialWilliam E Berger
Allergy and Asthma Associates of Southern California, Mission Viejo, CA, USA
Curr Med Res Opin 22:1217-26. 2006..CONCLUSIONS: In this study, levalbuterol administered via MDI significantly improved airway function in comparison with placebo in asthmatic children aged 4-11 years with a safety profile that was similar to placebo... - Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitisRobert A Nathan
Allergy and Asthma Associates, PC, Colorado Springs, Colorado 80907, USA
Ann Allergy Asthma Immunol 100:497-505. 2008..Intranasal corticosteroids are recommended as first-line therapy for the treatment of allergic rhinitis. Fluticasone furoate is a novel enhanced-affinity glucocorticoid for the treatment of allergic rhinitis... - A patient satisfaction survey comparing levalbuterol with racemic albuterol in childrenWilliam E Berger
Southern California Research, Mission Viejo, California 92691, USA
Allergy Asthma Proc 25:437-44. 2004..This study supports the conclusion that the majority of caregivers of children with asthma who have experience with both levalbuterol and racemic albuterol prefer levalbuterol over racemic albuterol... - Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitisWilliam E Berger
Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, 92691, USA
Ann Pharmacother 39:1984-9. 2005..A recent survey estimated that 85% of patients with allergic rhinitis experience nasal congestion. This symptom considerably impacts quality of life... - Acute bronchospasm from the patient's perspectiveWilliam E Berger
Department of Pediatrics, Division of Allergy and Immunology, College of Medicine, University of California, Irvine, USA
Postgrad Med 118:44-7; discussion 48. 2005..These research studies point out that a very real "communications gap" exists between physicians and patients when examined from the patient's perspective... - Current options in the treatment of acute bronchospasmWilliam E Berger
Department of Pediatrics, Division of Allergy and Immunology, College of Medicine, University of California, Irvine, USA
Postgrad Med 118:18-26. 2005..Better control allows for better patient health, reduced number of physician and emergency department visits, and reduced health care costs... - Asthma and COPD: definitions, epidemiology, and treatment guidelinesWilliam E Berger
Department of Pediatrics, Division of Allergy and Immunology, College of Medicine, University of California, Irvine, USA
Postgrad Med 118:2-8. 2005..Prevalence of asthma may be leveling off. Prevalence of COPD is increasing, especially in women. Although several therapies are available, many patients do not seek treatment until COPD is moderately advanced... - Efficacy and safety evaluation of ciclesonide in subjects with mild-to-moderate asthma not currently using inhaled corticosteroidsWilliam E Berger
Allergy and Asthma Associates of Southern California, Mission Viejo, California, USA
Allergy Asthma Proc 30:304-14. 2009..In this study, CIC80 b.i.d. improved disease control in subjects with mild-to-moderate persistent asthma not using an ICS and provided greater improvements than CIC160 q.d... - Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved complianceWilliam E Berger
Allergy and Asthma Associates, 27800 Medical Center Road, Suite 244, Mission Viejo, California 92691, USA
Expert Opin Drug Deliv 4:689-701. 2007..Findings suggest that the FF system should aid in improving attitudes to the use of intranasal corticosteroids amongst physicians and patients... - The use of inhaled corticosteroids for persistent asthma in infants and young childrenWilliam E Berger
Allergy and Asthma Associates of Southern California, Mission Viejo, California 92691, USA
Ann Allergy Asthma Immunol 92:387-399; quiz 399-402, 463. 2004..To review pediatric trials of inhaled corticosteroid (ICS) therapy and summarize data on the pediatric use of devices to facilitate delivery of ICSs... - What is new in antiimmunoglobulin E asthma therapyWilliam E Berger
Allergy and Asthma Associates, Mission Viejo Medical Center, Mission Viejo, California 92691, USA
Allergy Asthma Proc 26:428-34. 2005.... - The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomesWilliam E Berger
American College of Allergy, Asthma, and Immunology, Mission Viejo, California, USA
Ann Allergy Asthma Immunol 93:538-45. 2004..37; 95% CI, 0.05-2.69). CONCLUSIONS: Our findings suggest that refinements to the HEDIS measure method for identifying patients with persistent asthma may be needed... - Pediatric allergic rhinitis: antihistamine selectionWilliam E Berger
Allergy/Asthma Associates, Mission Viejo, California 92691, USA
Clin Pediatr (Phila) 44:655-64. 2005 - Access to allergy care: implications for quality healthcare and public safetyWilliam E Berger
Southern California Research, Mission Viejo, CA, USA
Manag Care Q 11:8-11. 2003..Any action to reduce or limit coverage will not only diminish the quality of medical care for allergy patients but have significant health and safety implications for the general public... - Judicious antibiotic use and intranasal corticosteroids in acute rhinosinusitisCatherine Butkus Small
Division of Infectious Diseases, Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla 10595, USA
Am J Med 120:289-94. 2007..The use of intranasal corticosteroids in acute rhinosinusitis therefore might reduce the inappropriate use of antimicrobial therapy in acute rhinosinusitis... - The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitisGeorge Philip
Merck Research Laboratories, Rahway, NJ, USA
Curr Med Res Opin 20:1549-58. 2004..005). CONCLUSION: Montelukast provides significant relief from symptoms of seasonal allergic rhinitis, while also conferring a benefit for asthma, in patients with both allergic rhinitis and asthma... - Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthmaCarlos E Baena-Cagnani
Department of Paediatrics, Infantile Hospital, Santa Rosa, Cordoba, Argentina
Int Arch Allergy Immunol 130:307-13. 2003..Asthma and seasonal allergic rhinitis (SAR) are recognized as manifestations of a single airway disease. Desloratadine has demonstrated efficacy in treating SAR symptoms, including nasal obstruction... - Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challengeBob Q Lanier
Fort Worth Allergy Asthma Association, Texas 76132, USA
Clin Ther 24:1161-74. 2002.... - Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadineCraig F LaForce
Carolina Allergy and Asthma Consultants, Raleigh, North Carolina 27607, USA
Ann Allergy Asthma Immunol 93:154-9. 2004..Currently available oral second-generation antihistamines do not provide adequate symptom relief for many allergy patients... - Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge modelMiguel Brodsky
Opthalmology Department, Israelita Medical Hospital, Buenos Aires, Argentina
Eye Contact Lens 29:113-6. 2003.... - Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitisEli O Meltzer
Allergy and Asthma Medical Group and Research Center, San Diego, California 92123, USA
Ann Allergy Asthma Immunol 95:600-6. 2005..A nasal spray containing the antiallergy agent olopatadine hydrochloride is being developed for the treatment of seasonal allergic rhinitis (SAR)... - Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthmaDavid S Pearlman
Colorado Allergy and Asthma Centers, PC, Denver 80230, USA
J Allergy Clin Immunol 116:1206-12. 2005..Inhaled corticosteroids are recommended as first-line therapy for persistent asthma... - Direct and indirect costs of asthma to an employerHoward G Birnbaum
Analysis Group/Economics, Cambridge, MA 02138, USA
J Allergy Clin Immunol 109:264-70. 2002..CONCLUSION: Failure to account fully for the broader consequences of asthma in terms of indirect and comorbid treatment costs would result in a significant underassessment of the cost of asthma to an employer... - The variability of asthmaKevin R Murphy
Midwest Children s Chest Physicians, Omaha, NE 68130, USA
Curr Med Res Opin 21:1519-26. 2005..Awareness of episodic changes in asthma severity, with subsequent tailored adjustment in guideline-based ICS therapy, should enable optimal control of asthma with minimal medication requirements... - Symptom severity assessment of allergic rhinitis: part 1Sheldon L Spector
Ann Allergy Asthma Immunol 91:105-14. 2003